A broad, versatile range of standard, custom and specialized parenteral controlled release excipients
The RESOMER® and LACTEL® portfolios provide an industry-leading selection of functional excipients for parenteral controlled release. As an expert provider of custom and specialized parenteral excipients, we offer an innovative and highly versatile portfolio which supports local and systemic delivery of complex parenteral formulations including microparticles, in-situ depots, nanoparticles and drug loaded implants.
Our RESOMER® portfolio has been delivering safety, biocompatibility and supply security to companies with complex parenteral drug products for more than 30 years. In 2020, Evonik acquired the LACTEL® absorbable polymers portfolio—first commercialized in 1987— from DURECT Corporation. Together, these absorbable polymers have been defining polymer quality for decades and find application in numerous FDA-approved pharmaceutical products.
Both portfolios are 100 percent bioresorbable, completely metabolized by the body (hence, bioabsorbable), and ideal for terminal sterilization. With a shelf life exceeding five years, RESOMER® and LACTEL® are highly suitable for use with small molecules, peptides, proteins and other substances. Both are supplied from modern, established manufacturing sites in the U.S. and Germany – ensuring extensive options for dual sourcing and supply security.
Our standard polymer portfolio - established quality for complex parenteral drug products for more than 30 years:
Our custom polymer portfolio - tailored to match the most specific API, formulation and parenteral drug product requirements:
RESOMER® standard catalog of high-quality biodegradable polymers
The standard RESOMER® catalog of biodegradable polymers for controlled release includes high and low molecular weight homo-polymers, co-polymers and block co-polymers. Standard compositions include Poly (D,L-lactide) and Poly (D,L-lactide-co-glycolide) polymers with acid and ester end group chemistries. The RESOMER® portfolio also includes specialized co-polymers manufactured via polycondensation and di-block co-polymers made of PLA and mPEG. A variety of molecular weights are available to help modulate degradation times from weeks to years.
All polymers are purified as part of the standard manufacturing process to achieve low residual monomer content and avoid possible interaction of any remaining monomer with an API. RESOMER® polymers are typically produced in conformance with the Joint IPEC- PQG Good Manufacturing Practice Guide for Bulk Pharmaceutical Excipients 2017 and USP-NF General Chapter GMPs for Bulk Pharmaceutical Excipients via validated manufacturing processes in large batch sizes from production sites in Germany or the U.S.
RESOMER® R is a platform of PLA / poly (D,L-lactide)-based biodegradable polymers for controlled release. Designed, in particular, for microparticles and drug-loaded implants, these amorphous polymers are available with either acid or ester end groups. Degradation times can vary from as little as a few weeks or less to nine months or more. Inherent Viscosities (IV) can range from 0.15 to 0.75 dL / g, with molecular weights between 10,000 and 28,000 Daltons. Polymer properties including crystallinity can be easily tuned to match specific formulation and release profile requirements.
| Polymer name | Inherent viscosity (dl/g) | Composition | Degradation timeframe* | End group |
|---|---|---|---|---|
| RESOMER® R 202 H | 0.16 - 0.24 | Poly(D,L-lactide) | < 6 months | Acid |
| RESOMER® R 203 H | 0.25 - 0.35 | Poly(D,L-lactide) | < 6 months | Acid |
| RESOMER® R 202 S | 0.16 - 0.24 | Poly(D,L-lactide) | < 9 months | Ester |
| RESOMER® R 203 S | 0.25 - 0.35 | Poly(D,L-lactide) | < 12 months | Ester |
| RESOMER® R 205 S | 0.55 - 0.75 | Poly(D,L-lactide) | < 18 months | Ester |
RESOMER® RG is a platform of PLGA / poly (D,L-lactide-co-glycolide)-based bioresorbable excipients for controlled release. Designed for use with a range of complex parenteral drug products, these amorphous polymers are also available with either acid or ester end groups. Standard mole ratios include 50:50, 65:35, 75:25 and 85:15. Degradation times can extend for up to 18 months or more. Inherent Viscosities (IV) can range from 0.09 to 1.7 dL / g, with molecular weights between 7,000 and 240,000 Daltons. Polymer properties including crystallinity can be easily tuned to match specific formulation and release profile requirements.
| Polymer name | Inherent viscosity (dl/g) | Composition | Degradation timeframe* | End group |
|---|---|---|---|---|
| RESOMER® RG 501 H | 0.08 - 0.16 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Acid |
| RESOMER® RG 502 | 0.16 - 0.24 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Ester |
| RESOMER® RG 502 H | 0.16 - 0.24 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Acid |
| RESOMER® RG 503 | 0.32 - 0.44 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Ester |
| RESOMER® RG 503 H | 0.32 - 0.44 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Acid |
| RESOMER® RG 504 | 0.45 - 0.60 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Ester |
| RESOMER® RG 504 H | 0.45 - 0.60 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Acid |
| RESOMER® RG 505 | 0.61 - 0.74 | Poly(D,L-lactide-co-glycolide) 50:50 | < 3 months | Ester |
| RESOMER® RG 653 H | 0.32 - 0.44 | Poly(D,L-lactide-co-glycolide) 65:35 | < 3 months | Acid |
| RESOMER® RG 750 S | 0.8 - 1.2 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Ester |
| RESOMER® RG 752 H | 0.14 - 0.22 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Acid |
| RESOMER® RG 752 S | 0.16 - 0.24 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Ester |
| RESOMER® RG 753 H | 0.32 - 0.44 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Acid |
| RESOMER® RG 753 S | 0.32 - 0.44 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Ester |
| RESOMER® RG 755 S | 0.50 - 0.70 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Ester |
| RESOMER® RG 756 S | 0.71 - 1.0 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Ester |
| RESOMER® RG 757 S | 0.9 - 1.3 | Poly(D,L-lactide-co-glycolide) 75:25 | < 6 months | Ester |
| RESOMER® RG 858 S | 1.3 - 1.7 | Poly(D,L-lactide-co-glycolide) 85:15 | < 9 months | Ester |
The synthesis of RESOMER® grades of Poly (D,L-lactide-co-clycolide) or PLGA via direct polycondensation eliminates any requirement for the use of tin as a catalyst. Two RESOMER® Condensate PLGA polymers with a 50:50 mole ratio are available as standard products without any tin content. Both are low molecular weight polymers with an Mn of 800 and 2,300 Daltons. Additional molecular weight ranges are possible via the RESOMER® Select platform for customization.
| Polymer name | Molecular weight | Composition |
|---|---|---|
| RESOMER® Condensate RG 50:50 Mn 800 | 700 - 900 g/mole | Poly(D,L-lactide-co-glycolide) 50:50 |
| RESOMER® Condensate RG 50:50 Mn 2300 | 2000 - 2500 g/mole | Poly(D,L-lactide-co-glycolide) 50:50 |
The RESOMER® RP d catalog includes di-block copolymers of poly(DL-lactide) and poly(ethylene glycol) incorporating various weight fractions of mPEG-5000. These amphiphilic polymers are available to help achieve shorter degradation times than standard lactide/glycolide-containing polymers and are especially suited for nanoparticle formation.
| Polymer name | Inherent viscosity (dl/g) | Composition | PEG (wt%) | Degradation timeframe* |
|---|---|---|---|---|
| RESOMER® RP d 155 | 0.55 – 0.68 | Poly(DL-lactide)-block-poly(ethylene glycol) methyl ether 5000, 15 wt.% PEG | 15 | < 2 months |
| RESOMER® RP d 255 | 0.39 – 0.49 | Poly(DL-lactide)-block-poly(ethylene glycol) methyl ether 5000, 25 wt.% PEG | 25 | < 2 months |
| RESOMER® RP d 335 | 0.33 – 0.42 | DL-lactide)-block-poly(ethylene glycol) methyl ether 5000, 33 wt.% PEG | 33 | < 2 months |
LACTEL® standard catalog of bioresorbable polymers for price sensitive applications
The standard LACTEL® portfolio boasts of more than 20 polymers available as a cost effective supply due to streamlined manufacturing processes. Common application areas for LACTEL standard polymers include veterinary medicine, where bioresorbable polymers are used in long-acting injectable formulations, and generic drug formulations, which require price-sensitive planning and quick shipment to support demanding, fast-paced markets. These non-solvent purified polymers are appropriate for many formulation applications, from existing generic products to novel therapeutics. For development projects, LACTEL® is available in small volumes that can then be scaled and optimized as a project progresses from small-scale research to full-scale commercial batches.
| Polymer name | Product no. | Polymer name | Abbrev | Inherent viscosity (IV) dL/g | End group | Degradation time*** |
|---|---|---|---|---|---|---|
| LACTEL® 50:50 DL-PLGE IV 0.15 - 0.25 | LACTEL® B6017-1 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.15 - 0.25* | Ester | < 3 months |
| LACTEL® 50:50 DL-PLGE IV 0.26 - 0.54 | LACTEL® B6010-1 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.26 - 0.54* | Ester | < 3 months |
| LACTEL® 50:50 DL-PLGE IV 0.55 - 0.75 | LACTEL® B6010-2 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.55 - 0.75* | Ester | < 3 months |
| LACTEL® 50:50 DL-PLGE IV 0.76 - 0.94 | LACTEL® B6010-3 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.76 - 0.94* | Ester | < 3 months |
| LACTEL® 50:50 DL-PLGE IV 0.95 - 1.20 | LACTEL® B6010-4 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.95 - 1.20* | Ester | < 6 months |
| LACTEL® 65:35 DL-PLGE IV 0.55 - 0.75 | LACTEL® B6001-1 | 65:35 Poly(D,L-lactide-co-glycolide) | 65:35 DL-PLG | 0.55 - 0.75* | Ester | < 4 months |
| LACTEL® 75:25 DL-PLGE IV 0.55 - 0.75 | LACTEL® B6007-1 | 75:25 Poly(D,L-lactide-co-glycolide) | 75:25 DL-PLG | 0.55 - 0.75** | Ester | < 6 months |
| LACTEL® B6007-2 | 75:25 Poly(D,L-lactide-co-glycolide) | 75:25 DL-PLG | 0.80 - 1.20** | Ester | < 6 months | |
| LACTEL® 85:15 DL-PLGE IV 0.55 - 0.75 | LACTEL® B6006-1 | 85:15 Poly(D,L-lactide-co-glycolide) | 85:15 DL-PLG | 0.55 - 0.75** | Ester | < 9 months |
| LACTEL® 85:15 DL-PLGE IV 0.76 - 0.85 | LACTEL® B6006-2 | 85:15 Poly(D,L-lactide-co-glycolide) | 85:15 DL-PLG | 0.76 - 0.85** | Ester | < 12 months |
| LACTEL® 50:50 DL-PLGA IV 0.15 - 0.25 | LACTEL® B6013-1 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.15 - 0.25* | Acid | < 3 months |
| LACTEL® 50:50 DL-PLGA IV 0.55 - 0.75 | LACTEL® B6013-2 | 50:50 Poly(D,L-lactide-co-glycolide) | 50:50 DL-PLG | 0.55 - 0.75* | Acid | < 3 months |
| LACTEL® 75:25 DL-PLGA IV 0.70 - 0.90 | LACTEL® B6012-4 | 75:25 Poly(D,L-lactide-co-glycolide) | 75:25 DL-PLG | 0.70 - 0.90** | Acid | < 6 months |
| Polymer name | Product no. | Polymer name | Abbrev | Inherent viscosity (IV) dL/g | End group | Degradation time*** |
|---|---|---|---|---|---|---|
| LACTEL® DL-PLE IV 0.26 - 0.54 | LACTEL® B6005-1 | Poly(D,L-lactide) | DL-PL | 0.26 - 0.54** | Ester | < 12 months |
| LACTEL® DL-PLE IV 0.55 - 0.75 | LACTEL® B6005-2 | Poly(D,L-lactide) | DL-PL | 0.55 - 0.75** | Ester | < 18 months |
| LACTEL® B6014-1 | Poly(D,L-lactide) | DL-PL | 0.16 - 0.25** | Acid | < 6 months |
The Glucose Star Polymer is a branched 55:45 DL-PLG that is highly purified to achieve nearly undetectable levels of residuals including tin and monomer. Developed specifically for the formulation of microspheres with octreotide, its branched nature provides unique drug delivery characteristics and may be beneficial for use in applications involving highly sensitive or reactive APIs.
| Polymer name | Product no. | Polymer name | Abbrev | Inherent viscosity (IV) dL/g | End group |
|---|---|---|---|---|---|
| LACTEL® 55:45 DL-PLG-Glu IV 0.40-0.60 | LACTEL® B6131-1 | 55:45 Poly(DL-lactide-co-glycolide), Glucose initiated | 55:45 DL-PLG-Glu | 0.40 - 0.60** | Hydroxyl |
ANY QUESTIONS? JUST CONTACT US.
"Our global team of formulation experts is ready to support you with all questions around our product and service portfolio for parenteral drug delivery. Contact us to profit from more than 30 years of application know-how!"
Ahmet Alici
Business Manager